Table 96Subgroup and sensitivity analyses: haloperidol vs. olanzapine - Positive symptoms (PANSS Scale)

Total SymptomsStudiesParticipantsEffect EstimateI2Favors
OVERALL POOLED RESULTS1437420.43 (−0.22,1.08)36%ND
Disorder subtypes
Schizoaffective disorder1761.20 (−2.07, 4.47)NEND
Mixed1336660.38 (−0.30, 1.07)41%ND
Co-morbid drug/alcohol use
Excluded4527−0.44 (−2.75, 1.87)51%ND
Included only131−2.00 (−4.82, 0.82)NEND
Mixed931840.70 (0.15, 1.26)17%olanzapine
Treatment resistance
Treatment resistant522070.26 (−1.26, 1.78)53%ND
No treatment resistance1442.18 (−0.59, 4.95)NEND
Mixed814910.32 (−0.51, 1.15)30%ND
Duration of followup
≤6 weeks258−2.08 (−4.59, 0.43)0%ND
>6 weeks and <6 months76940.21 (−1.19, 1.62)48%ND
≥6 months529900.77 (0.30, 1.24)0%olanzapine
Dosage of FGA (haloperidol)
≤20mg/d1235930.62 (0.03, 1.21)23%olanzapine
Upper limit >20mg/d2149−0.62 (−3.62, 2.38)60%ND
Dosage of SGA (olanzapine)
≤20mg/d1235930.62 (0.03, 1.21)23%olanzapine
>20mg/d2149−0.62 (−3.62, 2.38)60%ND
Source of funding
Industry funding1335600.33 (−0.38, 1.05)40%ND
No industry funding reported11821.15 (−0.55, 2.85)NEND
Risk of bias
Unclear1116880.45 (−0.36, 1.25)36%ND
High32054−0.12 (−2.21, 1.98)51%ND
Other1334660.34 (−0.36, 1.04)39%ND
Asian12761.30 (−0.65, 3.25)NEND
Data analysis
Imputed data2336−0.66 (−2.68, 1.36)68%ND
No imputed data1234060.74 (0.11, 1.37)17%olanzapine

Significant results are in bold. d = day; FGA = first generation antipsychotic; I2 = I–squared; mg = milligrams; ND = no difference; NE = not estimable; PANSS = Positive and Negative Syndrome Scale; SGA = second generation antipsychotic

From: Appendix M, Subgroup and Sensitivity Analyses

Cover of First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness
First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness [Internet].
Comparative Effectiveness Reviews, No. 63.
Abou-Setta AM, Mousavi SS, Spooner C, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.